Sars-Cov-2 Infections in CAR T Cell Recipients

s / Transplant Cell Ther 27 3S (2021) S1–S488 S211 (57%). Three of 7 (43%) were admitted with SARS-CoV-2 and of these 3, 2 were admitted to the intensive care unit. Five out of 7 (71%) had B-cell aplasia at the time of infection. Median admission length was 15 days (6-20; n=3). For maximal respiratory support, 1/7 (14%) required invasive mechanical ventilation, 1/7 (14%) required high flow nasal cannula, and (71%) 5/7 required no supplemental oxygen. Three of 7 (43%) had chest radiographs performed and 3/3 imaged had an infiltrate or ground glass opacities noted. Treatments included hydroxychloroquine (n=1), remdesivir (n=1), and steroids (n=2). After remdesivir and dexamethasone, fever resolved and respiratory status improved within 24 hours in 1 patient with severe COVID-19 (Fig. 1). Interferon-g was the most elevated serum cytokine in 1 patient admitted with severe COVID-19. One patient with bacteremia and refractory leukemia died from multisystem organ dysfunction, while all others recovered. Conclusion: In this cohort of CAR T cell recipients with SARS-CoV-2 positivity, 43% required admission, 86% recovered, and there was one patient death with co-occurring bacterial infection and sepsis. No cases of MIS-C were observed. Those without co-infection had favorable clinical outcomes.